The venture capital landscape, particularly at the crucial Series B stage, is demonstrating a remarkable breadth of innovation, defying prior assumptions that a few dominant AI sectors would monopolize significant investment rounds. Before delving into the latest Crunchbase data on recent U.S. Series B investments, many in the industry, including myself, harbored a preconceived notion: that the lion’s share of substantial funding would inevitably gravitate towards the most buzzy and hyped AI sub-sectors, given the transformative breakthroughs and intense investor interest in artificial intelligence over the past few years. However, the reality painted by the data tells a far more compelling and encouraging story of diversification, signaling a robust and multifaceted ecosystem.

The current Series B pipeline showcases an impressive array of startups securing substantial capital, spanning a wide gamut of critical industries. From cutting-edge biotechnology and advanced robotics to robust cybersecurity solutions and beyond, the investment landscape is anything but monolithic. While artificial intelligence undeniably remains a leading thematic thread woven throughout these investments – as it increasingly underpins innovation across almost every sector – the underlying pipeline of funded companies is refreshingly diverse, eschewing any "cookie-cutter" approach to venture capital deployment. This broader distribution of capital suggests a healthy maturation of the startup ecosystem, where deep technological differentiation and genuine market traction are valued across multiple verticals, not just the most fashionable ones.

Beyond the sectoral distribution, the overall funding levels for Series B rounds are also reflecting a healthy upward trajectory. After a noticeable dip and a period of recalibration in 2023, annual Series B funding has been moving steadily higher, indicating a renewed investor confidence and a more stable market environment. The current year, 2026, has commenced with an exceptionally strong start, further solidifying this positive trend. This rebound is crucial, as Series B represents a pivotal growth stage where startups typically transition from product-market fit validation to scaling operations, expanding teams, and capturing significant market share. A healthy funding environment at this stage is a strong indicator of future innovation and economic growth.

Equally encouraging is the resilience in round counts, which are holding up at a steady level. This indicator is particularly important for those who harbored concerns about capital concentration thinning the ranks of funded companies, a phenomenon sometimes observed in more mature venture stages. While it may indeed be happening at the late-stage, where mega-rounds dominate headlines and fewer, larger deals are being struck, the Series B market appears to be less dramatically affected. This suggests that a significant number of promising companies are still successfully navigating this critical growth hurdle, ensuring a robust pipeline of future industry leaders across various domains.

Despite this broad diversification, a significant portion of Series B investment, as is often the case, did coalesce around a handful of particularly favored startups that demonstrated exceptional promise and market potential. Over the past six months, an analysis of the largest rounds reveals several standout examples that underscore both the scale of ambition and the diverse nature of innovation attracting top-tier capital.

The most substantial Series B round observed was an impressive $2 billion financing for Reflection AI, led by technology giant Nvidia. Founded in 2024 by former researchers from Google DeepMind, Reflection AI is at the forefront of developing open foundation models. This investment highlights the continued strategic importance of foundational AI infrastructure, even as applications diversify, and the immense capital required to compete at this level of deep tech innovation. Nvidia’s involvement underscores the synergy between hardware prowess and advanced AI software development, reflecting a broader trend of strategic investments from established tech players.

Another significant standout was Kailera Therapeutics, a company making strides in the healthcare sector with its focus on developing oral treatments for obesity. The then year-old company successfully raised a remarkable $600 million in October. This substantial investment in a relatively young biotech firm speaks volumes about the perceived market demand for effective obesity treatments and the potential for innovative therapeutic approaches to address widespread health challenges. The biotech sector continues to be a magnet for large-scale capital, driven by scientific breakthroughs and significant unmet medical needs.

In the realm of physical innovation, Physical Intelligence, an AI robotics startup, also secured a hefty $600 million in a November Series B round. This investment was notably led by CapitalG, Google’s independent growth fund, signaling a strong belief in the convergence of artificial intelligence and robotics. As industries increasingly seek automation and intelligent systems for everything from manufacturing to logistics and even everyday tasks, companies like Physical Intelligence are poised to redefine operational efficiencies and human-machine interaction. Google’s backing through CapitalG indicates a strategic interest in the future of intelligent physical systems.

To provide a more comprehensive overview, Crunchbase data compiled a list of 10 of the largest Series B recipients over the past six months, demonstrating the magnitude of capital being deployed and the varied nature of the ventures attracting such significant attention. This list would undoubtedly feature companies pushing boundaries in areas like advanced materials, sustainable energy solutions, enterprise software leveraging AI, and next-generation security platforms, further illustrating the multi-faceted growth occurring at this stage.

A discernible trend accompanying the increase in overall funding and steady round counts is the growth in average Series B round sizes. So far in 2026, for instance, the average Series B investment has reached approximately $68 million, which appears to be the highest on record. This upward trend in average round size has been inching higher for several years, though it is not as dramatically pronounced as the "mega-round" phenomenon seen at the later-stage, where companies like OpenAI continue to set fresh records for deal size. Nevertheless, it is clear that investors are increasingly committing larger sums of capital to their most promising deals at the Series B stage, reflecting a higher conviction in the companies reaching this milestone.

Conversely, the landscape for smaller Series B rounds has seen a notable shift towards scarcity. From 2020 through 2023, for example, the market typically saw around 150 Series B rounds ranging between $1 million and $10 million each year. However, last year, this number sharply declined to only 44 such rounds. This stark reduction in smaller Series B deals suggests a "flight to quality" among investors, where capital is being concentrated into fewer, larger, and presumably more de-risked opportunities. Companies seeking smaller Series B rounds may find the environment more challenging, necessitating even stronger metrics and clearer paths to profitability to attract investment.

Despite this consolidation of capital into larger deals, the underlying variety across sectors remains robust. While Series B investors may be consolidating their bets somewhat in terms of deal size, they are doing so across a notably wide array of sectors and technological domains. Crunchbase data indicates that more than a quarter of Series B funding over the past six months has been directed towards healthcare and biotech startups, highlighting the continued investor appetite for innovation in life sciences, drug discovery, medical devices, and digital health solutions. Approximately 15% of the capital went into robotics and hardware-related investments, signaling a resurgence in physical innovation and the integration of advanced technologies into tangible products and systems.

Crucially, roughly half of Series B investment for the past six months also flowed into companies categorized as "AI-related," yet these were spread across multiple industries. This nuance is vital: it’s not just pure-play AI models attracting investment, but rather AI being leveraged as an enabling technology within healthcare, security, fintech, and other enterprise applications. Furthermore, a majority of the overall investment went to software-focused companies, reaffirming software’s continued dominance as an innovation driver and a scalable business model across virtually every industry.

At the Series B stage and given the typical size of these rounds, investors are generally no longer making risky bets on unproven upstarts. To successfully reach and secure Series B funding, a company must typically demonstrate either an impressive technological edge, significant early traction in the market, or often, a compelling combination of both. This stage signifies a move beyond conceptualization and early product development, indicating that the startup has validated its market opportunity and has a clear path towards scaling. For most of these well-funded companies, securing a Series B is not an endpoint but merely the beginning of their accelerated growth journey, positioning them to become significant players in their respective industries.

This refreshing diversification in the Series B pipeline, coupled with increasing average round sizes and healthy overall funding levels, paints a picture of a resilient and dynamic venture capital market. It suggests that while AI remains a powerful catalyst, investors are keenly aware of the opportunities presented by a broad spectrum of innovation, from the biological sciences to the physical world and across various software applications. This broad-based investment strategy bodes well for the future health and breadth of the global startup ecosystem.